Compare S&P500 ETF (SPY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs GeneDx Holdings Corp — how do they compare? S&P500 ETF trades at $778.54 (market cap $821.54B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: S&P500 ETF is far larger — about 406.7× GeneDx Holdings Corp's market cap, and S&P500 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and GeneDx Holdings Corp for 19 Days on average.
| SPY | WGS | |
|---|---|---|
Market Cap | $821.54B | $2.02B |
Volume | 40,070,358 | 734,640 |
52-Week High | $779.14 | $167.51 |
52-Week Low | $631.99 | $34.51 |
Typical Hold Time | 205 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY, tracking the S&P 500, trades at $773.97, down 0.42% over 24 hours, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF is near its pivot point of $774, with support at $771 and resistance at $777. Recent news highlights mixed sentiment, with some articles pointing to strong profit growth in 2026 but expectations of a slowdown in 2027, while others discuss defensive positioning and valuation concerns amid market volatility.
The outlook for SPY remains tied to broader market dynamics, with potential upside from continued corporate earnings growth but risks from economic slowdowns and elevated valuations. Investors face opportunities from historical year-end rallies cited by analysts, yet must weigh risks like margin debt warnings and profit growth deceleration. Key factors include upcoming economic data and institutional flows influencing near-term performance.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
